|
|
|
|
| LEADER |
01267nam a2200241 u 4500 |
| 001 |
EB002002316 |
| 003 |
EBX01000000000000001165217 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Eculizumab (Soliris)
|h Elektronische Ressource
|b Alexion Pharma Canada Corp. : indication: neuromyelitis optica spectrum disorder
|
| 246 |
3 |
1 |
|a Eculizumab (Soliris)
|
| 246 |
3 |
1 |
|a Clinical review report for eculizumab (Soliris)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, October 2020
|
| 300 |
|
|
|a 1 PDF file (105 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK567400
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a The objective of this report was to perform a systematic review of the beneficial and harmful effects of eculizumab 10 mg/mL intravenous infusion for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive
|